



#16

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: G.A. Demopulos et al. Attorney Docket No.: OMER117356
Application No.: 09/839,633 Group Art Unit: 3763
Filed: April 20, 2001
Title: IRRIGATION SOLUTION AND METHOD FOR INHIBITION OF PAIN
AND INFLAMMATION

INFORMATION DISCLOSURE STATEMENT

Seattle, Washington 98101

August 13, 2001

TO THE COMMISSIONER FOR PATENTS:

Applicants are aware of the information listed in the attached form that may be material to the prosecution of the above-identified patent application.


1. X Copies of the listed patents, publications, and other information are enclosed for the Examiner's use.
2. X A concise explanation of the relevance of document I.D. No. F1 (which is not in the English language), as presently understood by the individual designated under 37 C.F.R. § 1.56(c) most knowledgeable about its content, is that it was cited in the International Search Report in parent International Application No. PCT/US99/24672 as being a document of particular relevance.
3. X Pursuant to 37 C.F.R. § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the national application (other than a CPA), within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application, before the mailing date of a first Office Action on the merits, or before the mailing date of a first Office Action after the filing of an RCE.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

4. X The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.18 which may be required during the entire pendency of the application, or credit any overpayment, to Deposit Account No. 03-1740. This authorization also hereby includes a request for any extensions of time of the appropriate length required upon the filing of any reply during the entire prosecution of this application. A copy of this document is enclosed.

Respectfully submitted,

CHRISTENSEN O'CONNOR
JOHNSON KINDNESS^{PLLC}


Dennis K. Shelton
Registration No. 26,997
Direct Dial No. 206.695.1718

I hereby certify that this correspondence is being deposited with the U.S. Postal Service in a sealed envelope as first class mail with postage thereon fully prepaid and addressed to the Commissioner for Patents, Washington, D.C. 20231, on the below date.

Date: August 13, 2001


Carole Julian

DKS:cj

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100



INFORMATION CITED BY APPLICANTS THAT MAY BE MATERIAL TO THE
PROSECUTION OF THE SUBJECT APPLICATION

Applicants: G.A. Demopoulos et al. Attorney Docket No. OMER117356
 Application No.: 09/839,633 Group Art Unit: 3763
 Filed: April 20, 2001
 Title: IRRIGATION SOLUTION AND METHOD FOR INHIBITION OF PAIN
 AND INFLAMMATION

U.S. PATENT DOCUMENTS

*Examiner Initial	ID	Document No.	Date	Name
_____	U1	5,212,196	05/18/1993	House et al.
_____	U2	5,373,022	12/13/1994	Fawzi et al.
_____	U3	5,525,625	06/11/1996	Bridges et al.
_____	U4	5,767,064	06/16/1998	Sims et al.
_____	U5	5,800,385	09/01/1998	Demopoulos et al.
_____	U6	5,820,583	10/13/1998	Demopoulos et al.

FOREIGN PATENT DOCUMENTS

*Examiner Initial	ID	Document No.	Date	Country	Translation Provided	
					Yes	No
_____	F1	2040 510	02/17/1972	Germany		X
_____	F2	0 160 191 A1	11/06/1985	Europe		
_____	F3	0 166 937 A2	01/08/1986	Europe		
_____	F4	0 424 059 A1	04/24/1991	Europe		
_____	F5	WO 92/14453	09/03/1992	PCT		
_____	F6	0 538 469 A1	04/28/1993	Europe		
_____	F7	WO 94/06476	03/31/1994	PCT		

LAW OFFICES OF
 CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
 1420 Fifth Avenue
 Suite 2800
 Seattle, Washington 98101
 206.682.8100



F8	WO 94/23039	10/13/1994	PCT
F9	0 623 674 A1	11/09/1994	Europe
F10	WO 95/10280	04/20/1995	PCT
F11	WO 95/16449	06/22/1995	PCT
F12	WO 95/25795	09/28/1995	PCT
F13	WO 96/17869	06/13/1996	PCT
F14	WO 96/26738	09/06/1996	PCT
F15	WO 97/21445	06/19/1997	PCT
F16	WO 98/27098	06/25/1998	PCT
F17	WO 97/35855	10/02/1997	PCT
F18	WO 98/38997	09/11/1998	PCT
F19	WO 99/24023	05/20/1999	PCT
F20	WO 99/34792	07/15/1999	PCT
F21	WO 00/38684	07/06/2000	PCT

OTHER INFORMATION
(Including Author, Title, Date, Pertinent Pages, Etc.)

*Examiner Initial	ID	
_____	O1	Asano et al., "Pial Arteriolar Constriction to Systemic and Local Administration of Dexmedetomidine," <i>Anesthesiology</i> 83(3A):A153, 1995.
_____	O2	Bondarev et al., "Disorders of immunoreactivity in acute cholecystitis in middle-aged and elderly patients and their correction in preventing postoperative complications," <i>Klinicheskaja Khirurgiia</i> 9:27-29, 1990 (English abstract).
_____	O3	Bonnet and Osman, "Alpha 2 adrenergic agonists in pain management," <i>Medical Science Monitor</i> 3/Suppl. 1:10-16, 1997.
_____	O4	Buritova et al., "Selective cyclooxygenase-2 inhibition reduces carrageenan oedema and associated spinal c-Fos expression in the rat," <i>Brain Research</i> 715(1-2):217-220, 1996.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100



- O05 Chang et al., "The antiinflammatory action of guanabenz is mediated through 5-lipoxygenase and cyclooxygenase inhibition," *Eur. J. Pharmacol.* 142:197-205, 1987.
- O06 Chiari and Eisenach, "Antinociceptive Effects of RJR 2403, a Selective Nicotinic Agonist, in Male and Female Rats," *FASEB Journal* 12(4):920, 1998.
- O07 Corbett et al., "Intraocular adrenaline maintains mydriasis during cataract surgery," *British J. of Ophthalmology* 78(2):95-98, 1994 (abstract).
- O08 Decker et al., "Antinociceptive effects of the novel neuronal nicotinic acetylcholine receptor agonist, ABT-594, in mice," *European J. Pharmacol.* 346(1):23-33, 1998.
- O09 Donnelly-Roberts et al., "ABT-594 [(R)-5-(2-Azetidinylmethoxy)-2-Chloropyridine]: A Novel, Orally Effective Analgesic Acting via Neuronal Nicotinic Acetylcholine Receptors: I. *In Vitro* Characterization," *Journal of Pharmacology and Experimental Therapeutics* 285(2):777-786, 1998.
- O10 Engelhardt, "Pharmacology of Meloxicam, a New Non-Steroidal Anti-Inflammatory Drug With an Improved Safety Profile Through Preferential Inhibition of Cox-2," *British J. Rheumatol.* 35(suppl. 1):4-12, 1996.
- O11 Flacke, "Alpha₂-Adrenergic Agonists in Cardiovascular Anesthesia," *J. Cardiothoracic and Vascular Anesthesia* 6(3):344-359, 1992.
- O12 Gillart et al., "Effects of Local Clonidine for Prolongation of Akinesia After Peribulbar Block," *Anesthesiology* 81(3A):A941, 1994.
- O13 Gaumann et al., "Hyperpolarizing Afterpotentials in C Fibers and Local Anesthetic Effects of Clonidine and Lidocaine," *Pharmacology* 48(1):21-29, 1994.
- O14 Hay and de Belleruche, "Carrageenan-induced hyperalgesia is associated with increased cyclo-oxygenase-2 expression in spinal cord," *Neuroreport* 8(5):1249-1251, 1997.
- O15 Holladay et al., "Neuronal Nicotinic Acetylcholine Receptors as Targets for Drug Discovery," *J. Medicinal Chemistry* 40(26):4169-4194, 1997.
- O16 Ishiyama et al., "Mechanisms of Dexmedetomidine-Induces Cerebrovascular Effects in Canine *In Vivo* Experiments," *Anesth. Analg.* 81(6):1208-1215, 1995.
- O17 Jeon et al., "Pharmacological Evaluation of UK-14,304 Analogs at Cloned Human α Adrenergic Receptors," *Bioorganic & Medicinal Chemistry Letters* 5(19):2255-2258, 1995.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100



- O18 Joshi, "Postoperative Pain Management," *International Anesthesiology Clinics* 32(3):113-126, 1994.
- O19 Kanto, "The place of alpha-2-agonists in anesthesiology of today," *Acta Anaesthesiol. Scand.* 41:4-5, 1997.
- O20 Kulkarni et al., "Anti-inflammatory Actions of Clonidine, Guanfacine and B-HT 920 Against Various Inflammagen-Induced Acute Paw Oedema in Rats," *Arch. Int. Pharmacodyn.* 279:324-334, 1986.
- O21 Kyncl et al., "Novel Adrenergic Compounds. I. Receptor Interactions of ABBOTT-54741 [5,6-Dihydroxy-1,2,3,4-Tetrahydro-1-Naphtyl)Imidazoline], an α -Adrenergic Agonist," *J. Cardiovasc. Pharmacol.* 13:382-391, 1989.
- O22 Lydiatt et al., "A Prospective Double-Blind Evaluation of Cocaine, Phenylephrine With Xylocaine and Oxymetazoline With Xylocaine for Topical Intranasal Use," *American Journal of Rhinology* 3(2):105-112, 1989.
- O23 MacKenzie, Terrance A., and Earle R. Young, "Local Anesthetic Update," *Anesth. Prog.* 40(2):29-34, 1993.
- O24 Mehlich et al., "Analgesic efficacy and plasma levels of a highly selective inhibitor of COX-2 (SC-58635;SC) in patients with post-surgical dental pain," *Clinical Pharmacology & Therapeutics* 61(2):195, 1997.
- O25 Munk et al., "Synthesis and Evaluation of 2-[(5-Methylbenz-1-ox-4-azin-6-yl)imino]imidazoline, a Potent, Peripherally Acting α_2 Adrenoceptor Agonist," *J. Med. Chem.* 39:3533-3538, 1996.
- O26 Noorily et al., "Cocaine, Lidocaine, Tetracaine: Which Is Best for Topical Nasal Anesthesia?" *Anesth. Analg.* 81(4):724-727, 1995.
- O27 Noorily et al., "Intranasal anesthetic effects of lidocaine and tetracaine compared," *Otolaryngology - Head and Neck Surgery* 113(4):370-374, 1995.
- O28 Ogren and Caniglia, "Anesthesia for Rhinoplasty, *Anesthesia for Facial Plastic Surgery*, Thieme Medical Publishers, New York, 1993, pp. 51-53.
- O29 Osipova, "Antinociceptive Components of General Anesthesia and Postoperative Analgesia," *Anesteziologiya i Reanimatologiya* 5:11-15, 1998 (English abstract).
- O30 Pertovaara, "Antinociception Induced by Alpha-2-Adrenoceptor Agonists, With Special Emphasis on Medetomidine Studies," *Progress in Neurobiology* 40(6):691-709, 1993.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100



- O31 Reinhart et al., "Postoperative Analgesia After Peripheral Nerve Block for Podiatric Surgery: Clinical Efficacy and Chemical Stability of Lidocaine Alone Versus Lidocaine Plus Clonidine," *Anesth. Analg.* 83:760-765, 1996.
- O32 Reynolds, "Martindale - The Extra Pharmacopoeia Edition 31," Royal Pharmaceutical Society, London, GB, 1996, pp. 37 and 71.
- O33 Schweizer et al., "Inhibition of interleukin-1 (IL-1) enhanced pain reflexes in the rabbit by CGP 28238," *Agents and Actions* 32(1-2):67-69, 1991.
- O34 Seibert et al., "Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain," *Proc. Natl. Acad. Sci. USA* 91:12013-12017, 1994.
- O35 Smith and Taylor, "Monitored Anesthesia Care," *International Anesthesiology Clinics* 32(3):99-112, 1994.
- O36 Souter et al., "Controversies in the Perioperative Use of Nonsteroidal Antiinflammatory Drugs," *Anesth. Analg.* 79:1178-1190, 1994.
- O37 Taittonen et al., "Effect of clonidine and dexmedetomidine premedication on perioperative oxygen consumption and haemodynamic state," *Br. J. Anesth.* 78:400-406, 1997.
- O38 Talke et al., "Effects of Perioperative Dexmedetomidine Infusion in Patients Undergoing Vascular Surgery," *Anesthesiology* 82(3):620-633, 1995.
- O39 Tarver et al., "A comparison of cocaine vs. lidocaine with oxymetazoline for use in nasal procedures," *Otolaryngology - Head and Neck Surgery* 109(4):653-659, 1993 (abstract).
- O40 Thorig and Bill, "Effects of B-HT 920 in the eye and on regional blood flows in anesthetized and conscious rabbits," *Current Eye Research* 5(8):565-573, 1986.
- O41 Tong and Eisenach, " α_2 -Adrenergic Agonists," *Anesthesiology Clinics of North America* 12(1):49-63, 1994.
- O42 Tschernko et al., "Clonidine Added to the Anesthetic Solution Enhances Analgesia and Improves Oxygenation After Intercoastal Nerve Block for Thoracotomy," *Anesth. Analg.* 87:107-111, 1998.
- O43 Verma and Kulkarni, " α_2 -Adrenoceptor- and D₂-dopamine receptor-mediated analgesic response of B-HT 920," *J. Pharm. Pharmacol.* 43:131-133, 1991.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

_____ O44 Zhang et al., "Interaction of the nicotinic agonist (R,S)-3-pyridyl-1-methyl-2(3-pyridyl)-azetidine (MPA) with nicotinic acetylcholine receptor subtypes expressed in cell lines and rat cortex," *Neurochemistry Int.* 32:435-441, 1998.

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
lrk

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100